↓ Skip to main content

Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, November 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#39 of 369)
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

policy
1 policy source
twitter
18 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
67 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy
Published in
Journal of Pharmaceutical Policy and Practice, November 2016
DOI 10.1186/s40545-016-0088-0
Pubmed ID
Authors

Raffaella Ravinetto, Daniel Vandenbergh, Cécile Macé, Corinne Pouget, Brigitte Renchon, Jean Rigal, Benedetta Schiavetti, Jean-Michel Caudron

Abstract

The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries. Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in pharmaceutical quality between the North and the South remains important, and insufficiently addressed. More advocacy is needed for universal access to quality-assured medicines. It should target all those who are strongly "involved" with medicines: regulators, international organizations, journalists, purchasers, prescribers, program managers, policy makers, public health actors and the patients. Advocacy should be based on evidence from research and monitoring programs, and technical concepts should be translated in lay language through communication tools that address all the stakeholders. The fight to ensure universal access to quality medicines needs the participation of all, and can only be successful if grounded in common understanding.

Twitter Demographics

The data shown below were collected from the profiles of 18 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 67 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 22%
Student > Master 14 21%
Researcher 6 9%
Student > Bachelor 4 6%
Other 3 4%
Other 7 10%
Unknown 18 27%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 18 27%
Medicine and Dentistry 10 15%
Nursing and Health Professions 5 7%
Social Sciences 5 7%
Biochemistry, Genetics and Molecular Biology 2 3%
Other 8 12%
Unknown 19 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 March 2018.
All research outputs
#1,873,425
of 20,578,028 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#39
of 369 outputs
Outputs of similar age
#39,785
of 311,520 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#3
of 27 outputs
Altmetric has tracked 20,578,028 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 369 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,520 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.